CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution.

Trial Profile

CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Agatolimod (Primary)
  • Indications Acute myeloid leukaemia; Germ cell and embryonal neoplasms; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 May 2010 Planned number of patients changed from 25 to 16 as reported by ClinicalTrials.gov.
    • 19 May 2010 Planned end date changed from 1 Aug 2008 to 1 May 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top